Moneycontrol
Last Updated : Jan 29, 2018 01:21 PM IST | Source: Moneycontrol.com

Strides Shasun gains 5% on USFDA nod for Tenofovir that treats HIV, hepatitis B infection

Tenofovir Disoproxil Fumarate tablet is a generic version of Gilead's Viread tablet, for which the patent expired on January 25, 2018.

Strides Shasun shares rallied 4.55 percent intraday Monday after its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for Tenofovir Disoproxil Fumarate tablets, 300 mg from the US Food and Drug Administration.

Tenofovir Disoproxil Fumarate tablet is a generic version of Gilead's Viread tablet, for which the patent expired on January 25, 2018.

Strides is launching the product immediately as it already had a tentative approval for the product from USFDA for supplying under US President's Emergency Plan for AIDS Relief program and was able to obtain expedited review of its ANDA application.

At 11:02 hours IST, the stock price was quoting at Rs 804.55, up Rs 13.55, or 1.71 percent on the BSE.

Tenofovir Disoproxil Fumarate tablet is indicated in combination with other antiretroviral agents for treatment of HIV-1 infection in adults. It is also used for the treatment of chronic hepatitis B in adults.

According to IMS data, the US market for Tenofovir Disoproxil Fumarate is approximately USD 750 million.

Strides said the product will be manufactured at its oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc in the US market.

Meanwhile, pharma major Cipla also received approval from the USFDA for same drug, but the stock was trading flat (at the time of writing this article) after rising as much as 1.2 percent in early trade.

At 11:02 hours IST, Cipla was quoting at Rs 621.15, down Rs 0.15, or 0.02 percent on the BSE.
First Published on Jan 29, 2018 11:13 am
Loading...
Sections
Follow us on
Available On